Patents by Inventor Jeffrey L. Edelman

Jeffrey L. Edelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20210121397
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Application
    Filed: January 5, 2021
    Publication date: April 29, 2021
    Inventors: Jeffrey L. EDELMAN, Patrick M. HUGHES, Thomas C. MALONE, Gerald W. DEVRIES, Joan-En CHANG-LIN, Jane-Guo SHIAH, Thierry NIVAGGIOLI, Lon T. SPADA, Wendy M. BLANDA
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10881608
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: January 5, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20190365786
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Application
    Filed: December 24, 2018
    Publication date: December 5, 2019
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10493082
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: December 3, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20190038551
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 7, 2019
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 10188667
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: January 29, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
    Patent number: 10188665
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: January 29, 2019
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 10076492
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20180147217
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Application
    Filed: June 30, 2017
    Publication date: May 31, 2018
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES
    Publication number: 20180125861
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Application
    Filed: November 20, 2017
    Publication date: May 10, 2018
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
    Patent number: 9820995
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: November 21, 2017
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Pharmaceutical compositions and methods of use of 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9717743
    Abstract: The present invention relates to pharmaceutical compositions comprising 4-pregenen-11?-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).
    Type: Grant
    Filed: September 12, 2014
    Date of Patent: August 1, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Jeffrey L. Edelman, Alissar Nehme
  • 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES
    Publication number: 20170182062
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Application
    Filed: August 4, 2016
    Publication date: June 29, 2017
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • 4-pregenen-11?-17-21-triol-3,20-dione derivatives
    Patent number: 9433631
    Abstract: The present invention relates to novel 4-pregenen-11?-17-21-triol-3,20-dione derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals, as modulators of glucocorticoid or mineralocorticoid receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with glucocorticoid or mineralocorticoid receptor modulation.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: September 6, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Alissar Nehme, Thomas C. Malone
  • BIODEGRADABLE INTRAVITREAL TYROSINE KINASE IMPLANTS
    Publication number: 20160199297
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol.
    Type: Application
    Filed: January 11, 2016
    Publication date: July 14, 2016
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • OCULAR THERAPY USING GLUCOCORTICOID DERIVATIVES SELECTIVELY PENETRATING POSTERIOR SEGMENT TISSUES
    Publication number: 20160158249
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Application
    Filed: February 15, 2016
    Publication date: June 9, 2016
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
    Patent number: 9259429
    Abstract: Ophthalmically therapeutic materials, such as liquid-containing compositions and polymeric drug delivery systems, include a therapeutic component that includes an Glucocorticoid Derivative which, upon delivery to the posterior segment of a mammalian eye, does not significantly diffuse to the anterior segment of said eye. Methods of making and using the present materials are also described.
    Type: Grant
    Filed: August 19, 2014
    Date of Patent: February 16, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison
  • Biodegradable intravitreal tyrosine kinase implants
    Patent number: 9233070
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Jeffrey L. Edelman, Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Joan-En Chang-Lin, Jane-Guo Shiah, Thierry Nivaggioli, Lon T. Spada, Wendy M. Blanda
  • STEROID CONTAINING DRUG DELIVERY SYSTEM
    Publication number: 20150265633
    Abstract: Pharmaceutical composition for intraocular use comprising a glucocorticoid derivative, such as beclomethasone 17,21-diproprionate admixed with a biodegradable polymer such as a poly(lactide-co-glycolide) polymer or a high molecular weight polymeric hyaluronic acid are disclosed.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 24, 2015
    Inventors: Jeffrey L. Edelman, Kelly M. Harrison, Patrick M. Hughes, Lon T. Spada
  • Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
    Patent number: 8968766
    Abstract: Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: March 3, 2015
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Thomas C. Malone, Gerald W. DeVries, Jeffrey L. Edelman, Joan-En Lin, Jane-Guo Shiah, Thierry Nivaggioli